Nexign and MegaFon Introduced the Unified Billing to Facilitate Digital Transformation
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, and MegaFon, the pan-Russian operator of digital opportunities, have completed the project of unifying billing systems for all 8 MegaFon’s subsidiaries on a single BSS platform. The companies also migrated subscriber data to the new environment with no impact on customers.
The need to go beyond classical telecom services pushed MegaFon to transform the billing core and develop a unified billing system in order to facilitate digital transformation. Among the strategic goals of the project were the reduction of total cost of ownership (TCO) by 20–30% and acceleration of new product launches.
In the course of the project, 7 billing systems utilized in MegaFon were replaced with a single solution. The process was seamless for customers, and the specifics and working arrangements of individual organizations was taken into account during the migration of the B2X segment.
MegaFon achieved the following results:
- Unification of processes for all branch offices;
- Transition from a regional-based to a single shared operation service, which resulted in the increase of its efficiency;
- The product portfolio aligned within all branches of the operator while maintaining the flexibility of local pricing policy;
- Introduction of joint call centers with the same service KPIs and standardized routes for handling calls;
- Improved quality of customer service in the operator’s coverage area;
- Time to market (TTM) for various product categoriesreduced by 2-5 times.
“The collaboration with Nexign has proven to be efficient and successful. We pursued a number of goals traditional for large companies. Aside from optimizing TCO and shortening the time to market for new services, we aimed to improve the customer experience and, as a result, facilitate digital and business transformation. We managed to move all 8 subsidiaries to unified billing processes and switch to a single operation service, which minimized support costs and enabled us to develop an ecosystem for the seamless integration of external partners,” says Sergey Nikiforets, Director of Digital Services at MegaFon PJSC .
Besides the actual implementation of the unified billing system, a number of related projects were completed:
- The integration of the FastTrack methodology designed to automate the update implementation process. Consequently, the team responsible for it decided to spend no more than two weeks on minor changes to the system core — a process that used to last for about a year.
- Development of a microservice factory. Its goal was to accelerate the formation of a partner ecosystem. By using this tool, MegaFon has already launched more than 100 new business projects.
- The introduction of a product catalog that acts as a single point of development and modification of MegaFon’s products and services.
“The joint project with MegaFon is unique for the telecommunications market — both in terms of organized interaction and in terms of results achieved. The Nexign team carried out a comprehensive transformation of the operator’s systems, which enabled MegaFon to not only improve business efficiency and enter a new phase of development, but also to ensure customer loyalty while maintaining a high level of service in all regions. Whereas MegaFon will be able to upgrade the unified billing system to address short-term and long-term business challenges, Nexign’s scalable expertise will benefit telcos looking to develop digital services,” says Igor Gorkov, CEO of Nexign.
Nexign, a part of Intellectual Computer Systems Holding (ICS Holding) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering value-driven, high-performance product solutions since 1992. Headquartered in St. Petersburg, Nexign employs more than 1,800 people. The company has offices and subsidiaries through Russia, the Commonwealth of Independent States, the Middle East, Africa and LATAM.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RoboSense Teams Up With Webasto On Smart Roof Module With Integrated MEMS LiDAR23.4.2021 20:00:00 CEST | Press release
During the Shanghai Auto Show, RoboSense (https://robosense.ai/), a smart and automotive LiDAR system provider, and Webasto (https://www.webasto-group.com/), the global Top 100 automotive supplier and market leader for roof systems, announced cooperation on the Smart Roof Sensor Module that integrated with RoboSense automotive-grade MEMS LiDAR RS-LiDAR-M1 for Level 3 to Level 5 autonomous driving vehicles, largely simplifying the structure and mounting process of conventional sensor sets of self-driving vehicles and ensures advanced safety perception. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005484/en/ The M1 is seamlessly embedded into Webasto Roof Sensor Module (Photo: Business Wire) Through this strategic cooperation, Webasto is committed to seamlessly embedding the RoboSense M1, camera and other sensor systems to the panoramic roof of vehicles to provide safer and more reliable environment perception informat
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 202123.4.2021 16:05:00 CEST | Press release
LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021. Tralokinumab is a high affinity, human monoclonal antibody that specifically binds to and inhibits the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.2,3 It is an investigational therapy in clinical development, and its safety and efficacy are currently being evaluated by regulatory authorities. The interim analysis at 56 weeks in the ECZTEND trial (NCT03587805) showed tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) demonstrated long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms.1 Patients who had enrolled in pivotal Phase 3 trials ECZTRA 1 and 2 who continued into ECZTEND w
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD ® Use During the COVID-19 Pandemic23.4.2021 15:11:00 CEST | Press release
Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine tablets), which may contribute to their ability to fight infections and develop protective antibodies from vaccines. The data were presented at the 2021 American Academy of Neurology (AAN) Annual Meeting that was held virtually 17-22 April 2021. In the MAGNIFY-MS study, reduction of memory B cells occurred as early as one month after MAVENCLAD initiation with lowest levels sustained for up to 12 months, while naïve B cells, which are typically required for the generation of antibody responses following vaccination, began recovering immediately. Previously shared data from MAGNIFY-MS indicated that patients receiving MAVENCLAD are able to mount responses to influenza and varicella zoster vaccines, irrespec
Xsolla Offers Exit Strategies to Game Studios for Exit Advising and Planning23.4.2021 15:00:00 CEST | Press release
Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, has announced Xsolla Exit Strategies. The new service will connect development studios with financial and transaction advisors, guiding them through the process of selling their game property or studio, from due diligence preparation to exiting. The unveil of Xsolla Exit Strategies comes full circle from Xsolla Funding Club, launched March 2019, which provides matchmaking between vetted game projects and qualified investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005013/en/ Let Xsolla Exit Strategies match you with a financial and transaction advisor to help meet your exit goals. (Graphic: Business Wire) The gaming industry continues to flourish as demand is high for strategic partnerships and acquisitions for both game companies
Wipro Achieves Google Cloud Partner Specialization in Application Development23.4.2021 14:33:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has achieved the Google Cloud Partner Specialization in application development. This marks the fourth Partner Specialization badge that Wipro has received from Google Cloud, following recognition for outstanding cloud security, migration, and work transformation. This specialization demonstrates Wipro’s capabilities across multiple areas as a Google Cloud SI partner. As a trusted Google Cloud partner, Wipro can help customers leverage the best of Google Cloud platform as they develop and manage cloud-native business applications, enabling faster time to market, increasing scalability of applications and integrating them with external and internal systems in the IT landscape. This specialization will allow Wipro’s team of certified professionals to accelerate the customer modernization journey, increase agility and adapta
LEO Pharma Receives Positive CHMP Opinion of Adtralza ® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis23.4.2021 13:59:00 CEST | Press release
LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The CHMP positive opinion is one of the final steps before the European Commission makes its decision on the Marketing Authorization Application for use of Adtralza, an investigational therapy in clinical development, throughout the European Union. This final decision is expected in the coming months and if authorized, Adtralza will be the first fully human, monoclonal antibody available to specifically target the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms. Adtralza specifically targets IL-13 with high affinity and is developed to improve the symptoms of atopic derma
Schlumberger Announces First-Quarter 2021 Results23.4.2021 12:50:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the first-quarter 2021. First-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2021 Dec. 31, 2020 Mar. 31, 2020 SequentialYear-on-yearRevenue* $5,223 $5,532 $7,455 -6% -30% Income (loss) before taxes - GAAP basis $386 $471 $(8,089) -18% n/m Net income (loss) - GAAP basis $299 $374 $(7,376) -20% n/m Diluted EPS (loss per share) - GAAP basis $0.21 $0.27 $(5.32) -22% n/m Adjusted EBITDA** $1,049 $1,112 $1,347 -6% -22% Adjusted EBITDA margin** 20.1% 20.1% 18.1% 0 bps 203 bps Pretax segment operating income** $664 $654 $776 1% -14% Pretax segment operating margin** 12.7% 11.8% 10.4% 88 bps 230 bps Net income, excluding charges & credits** $299 $309 $351 -3% -15% Diluted EPS, excluding charges & credits** $0.21 $0.22 $0.25 -5% -16% Revenue by Geography International $4,211 $4,343 $5,225 -3% -19% North America* 972 1,167 2,180 -17% -55% Other 40 22 50 n/m n/m $5,223 $5,532 $7,455 -6% -30%
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom